Low-dose intravenous immunoglobulin (IVIg) in different immune-mediated conditions
Autoimmunity Reviews · 2023-11 · 22 (11) · 103451
DOI: 10.1016/j.autrev.2023.103451 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Autoimmunity Reviews, 2023-11. Verfasst von Maria Giovanna Danieli und 4 weiteren Autor:innen. Beteiligte Einrichtung: SOS Immunologia delle Malattie Rare e dei Trapianti, AOU delle Marche e Università Politecnica delle Marche, Ancona, Italy; Postgraduate School of Al…. Hauptthemen laut MEDLINE: Autoimmune Diseases, Immunologic Deficiency Syndromes. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
IVIg has been used for a long time as a replacement therapy for primary and secondary immunodeficiencies. Beside this supplementary role, when used at higher doses (i.e., 2 g/kg/monthly) it exerts an immunomodulatory role able to control multiple autoimmune and systemic inflammatory diseases. Several mechanisms of action have been described and hypothesized, nonetheless a synergistic action on the different component of the immune response seems to be crucial. The other side of the coin are the costs which showed an increase during the years due to the production of highly purified preparations which limit side reactions. This renders the product not easily accessible especially for low-income countries. Moreover, it is based on plasma donations that experienced a significant shrinkage after the COVID-19 pandemic and the consequences are still impactful. Due to the above-mentioned problems different authors tried to find out if a lower dosage of IVIg (< 2 g/kg/monthly) might exert an immunoregulatory role. In this review we aimed to summarize the current literature about a possible beneficial effect of a lower dosage of IVIg in multiple conditions that would help to treat a vast majority of patients. Even though in some cases (e.g., Kawasaki disease and immune thrombocytopenia) results are promising, for other conditions more research is needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- SOS Immunologia delle Malattie Rare e dei Trapianti, AOU delle Marche e Università Politecnica delle Marche, Ancona, Italy; Postgraduate School of Allergy and Clinical Immunology, Università Politecnica delle Marche, An…
- Postgraduate School of Internal Medicine, Università Politecnica delle Marche, Ancona, Italy.
- Postgraduate School of Allergy and Clinical Immunology, Università Politecnica delle Marche, Ancona, Italy.
- Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Reichman University Herzliya, Israel. Electronic address: yehuda.shoenfeld@sheba.health.gov.il.
Zitieren
APA
Danieli, M. G., Antonelli, E., Auria, S., Buti, E., & Shoenfeld, Y. (2023). Low-dose intravenous immunoglobulin (IVIg) in different immune-mediated conditions. Autoimmunity Reviews, 22(11), 103451. https://doi.org/10.1016/j.autrev.2023.103451
Vancouver
Danieli MG, Antonelli E, Auria S, Buti E, Shoenfeld Y. Low-dose intravenous immunoglobulin (IVIg) in different immune-mediated conditions. Autoimmunity Reviews. 2023;22(11):103451. doi:10.1016/j.autrev.2023.103451
BibTeX
@article{Danieli2023,
author = {Danieli, Maria Giovanna and Antonelli, Eleonora and Auria, Stefania and Buti, Elena and Shoenfeld, Yehuda},
title = {Low-dose intravenous immunoglobulin (IVIg) in different immune-mediated conditions},
journal = {Autoimmunity Reviews},
year = {2023},
volume = {22},
number = {11},
pages = {103451},
doi = {10.1016/j.autrev.2023.103451}
}
EUVIMED